Featured Research

from universities, journals, and other organizations

Compound reverses symptoms of Alzheimer's disease in mice

Date:

May 20, 2014

Source:

Saint Louis University Medical Center

Summary:

Research in an animal model supports the potential therapeutic value of an antisense compound to treat Alzheimer's disease. The molecule also reduced inflammation in the part of the brain responsible for learning and memory. The article is the second mouse study that supports the potential therapeutic value of an antisense compound in treating Alzheimer's disease in humans.

Share This

A molecular compound developed by Saint Louis University scientists restored learning, memory and appropriate behavior in a mouse model of Alzheimer's disease, according to findings in the May issue of the Journal of Alzheimer's Disease. The molecule also reduced inflammation in the part of the brain responsible for learning and memory. (stock image)

A molecular compound developed by Saint Louis University scientists restored learning, memory and appropriate behavior in a mouse model of Alzheimer's disease, according to findings in the May issue of the Journal of Alzheimer's Disease. The molecule also reduced inflammation in the part of the brain responsible for learning and memory.

Related Articles

The paper, authored by a team of scientists led by Susan Farr, Ph.D., research professor of geriatrics at Saint Louis University, is the second mouse study that supports the potential therapeutic value of an antisense compound in treating Alzheimer's disease in humans.

"It reversed learning and memory deficits and brain inflammation in mice that are genetically engineered to model Alzheimer's disease," Farr said. "Our current findings suggest that the compound, which is called antisense oligonucleotide (OL-1), is a potential treatment for Alzheimer's disease."

Farr cautioned that the experiment was conducted in a mouse model. Like any drug, before an antisense compound could be tested in human clinical trials, toxicity tests need to be completed.

Antisense is a strand of molecules that bind to messenger RNA, launching a cascade of cellular events that turns off a certain gene.

In this case, OL-1 blocks the translation of RNA, which triggers a process that keeps excess amyloid beta protein from being produced. The specific antisense significantly decreased the overexpression of a substance called amyloid beta protein precursor, which normalized the amount of amyloid beta protein in the body. Excess amyloid beta protein is believed to be partially responsible for the formation of plaque in the brain of patients who have Alzheimer's disease.

Scientists tested OL-1 in a type of mouse that overexpresses a mutant form of the human amyloid beta precursor gene. Previously they had tested the substance in a mouse model that has a natural mutation causing it to overproduce mouse amyloid beta. Like people who have Alzheimer's disease, both types of mice have age-related impairments in learning and memory, elevated levels of amyloid beta protein that stay in the brain and increased inflammation and oxidative damage to the hippocampus -- the part of the brain responsible for learning and memory.

"To be effective in humans, OL-1 would need to be effective at suppressing production of human amyloid beta protein," Farr said.

Scientists compared the mice that were genetically engineered to overproduce human amyloid beta protein with a wild strain, which served as the control. All of the wild strain received random antisense, while about half of the genetically engineered mice received random antisense and half received OL-1.

The mice were given a series of tests designed to measure memory, learning and appropriate behavior, such as going through a maze, exploring an unfamiliar location and recognizing an object.

Scientists found that learning and memory improved in the genetically engineered mice that received OL-1 compared to the genetically engineered mice that received random antisense. Learning and memory were the same among genetically engineered mice that received OL-1 and wild mice that received random antisense.

They also tested the effect of administering the drug through the central nervous system, so it crossed the blood brain barrier to enter the brain directly, and of giving it through a vein in the tail, so it circulated through the bloodstream in the body. They found where the drug was injected had little effect on learning and memory.

"Our findings reinforced the importance of amyloid beta protein in the Alzheimer's disease process. They suggest that an antisense that targets the precursor to amyloid beta protein is a potential therapy to explore to reversing symptoms of Alzheimer's disease," Farr said.

More From ScienceDaily

More Mind & Brain News

Featured Research

Mar. 31, 2015 — Memory and as well as connections between brain cells were restored in mice with a model of Alzheimer's given an experimental cancer drug, researchers report. "With this treatment, cells under ... full story

Mar. 31, 2015 — A criminologist finds that solitary confinement does not deter inmates from committing further violence in prison. The prisoners in the study who received solitary confinement were no more -- or less ... full story

Mar. 31, 2015 — Alcoholism takes a toll on every aspect of a person's life, including skin problems. Now, a new research report helps explain why this happens and what might be done to address it. "The clinical ... full story

Mar. 31, 2015 — Human language likely developed quite rapidly into a sophisticated system, a linguist contends. Instead of mumbles and grunts, people deployed syntax and structures resembling the ones we use today, ... full story

Mar. 31, 2015 — Coronary heart disease and stroke, two of the leading causes of death in the United States, are diseases associated with heightened platelet reactivity. A new study in humans suggests an underlying ... full story

Mar. 31, 2015 — A new study had researchers seeking answers to why the therapeutic benefit afforded by SSRIs was so limited in children and teenagers. If researchers can uncover the biological mechanisms preventing ... full story

Mar. 31, 2015 — During prenatal development, the brains of most animals, including humans, develop specifically male or female characteristics. But scientists have known little about the details of how this ... full story

Mar. 31, 2015 — A history of depression may put women at risk for developing diabetes during pregnancy, according to research. This study also pointed to how common depression is during pregnancy and the need for ... full story

Mar. 31, 2015 — Women who are abused by their partner or ex-partner are much less likely to use contraception; this exposes them to sexually transmitted diseases and leads to more frequent unintended pregnancies and ... full story

Featured Videos

AAA: Distracted Driving a Serious Teen Problem

AP (Mar. 25, 2015) — While distracted driving is not a new problem for teens, new research from the AAA Foundation for Traffic Safety says it&apos;s much more serious than previously thought. (March 25)
Video provided by AP

Many Don't Know They Have Alzheimer's, But Their Doctors Do

Newsy (Mar. 24, 2015) — According to a new study by the Alzheimer&apos;s Association, more than half of those who have the degenerative brain disease aren&apos;t told by their doctors.
Video provided by Newsy

A Quick 45-Minute Nap Can Improve Your Memory

Newsy (Mar. 23, 2015) — Researchers found those who napped for 45 minutes to an hour before being tested on information recalled it five times better than those who didn&apos;t.
Video provided by Newsy

Related Stories

Aug. 5, 2014 — Researchers have discovered a new drug compound that reverses the brain deficits of Alzheimer's disease in an animal model. The compound, TC-2153, inhibits the negative effects of a protein ... full story

Oct. 3, 2012 — New research proves the validity of one of the most promising approaches for combating Alzheimer's disease with medicines that treat not just some of the symptoms, but actually stop or prevent ... full story

ScienceDaily features breaking news and videos about the latest discoveries in health, technology, the environment, and more -- from major news services and leading universities, scientific journals, and research organizations.